HCM

和黄医药
NASDAQ

实时行情|Nasdaq Last Sale

31.52
-0.62
-1.93%
盘后: 31.52 0 0.00% 16:45 08/07 EDT
开盘
31.58
昨收
32.14
最高
31.88
最低
31.05
成交量
32.56万
成交额
--
52周最高
32.50
52周最低
14.74
市值
44.79亿
市盈率(TTM)
-385.3301
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测HCM价格均价为35.28,最高价位45.00,最低价为29.91。

EPS

HCM 新闻

更多
和黄医药将在上海建大型肿瘤药生产基地
中新经纬 · 2天前
和黄医药将在上海建大型肿瘤药生产基地,已与张江集团签合同
澎湃新闻 · 2天前
和黄医药:18个月内会有多个新药推向市场 回港上市只是时间问题
智通财经网 · 2天前
和黄医药(HCM.US): 待产品成功商业化才会重启香港上市,预计2024年达到收支平衡
智通财经网 · 3天前
Hutchison China MediTech Limited (HCM) CEO Christian Hogg on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 5天前
Hutchison China MediTech Limited (HCM) Q2 2020 Earnings Call Transcript
Image source: The Motley Fool. Hutchison China MediTech Limited (NASDAQ: HCM)Q2 2020 Earnings CallJul 30, 2020, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Mr.
Motley Fool · 07/31 03:01
Hutchison China MediTech reports 1H results
Hutchison China MediTech (NASDAQ:HCM): 1H GAAP EPADS of -$0.36. Revenue of $106.77M (+4.5% Y/Y) Press Release
seekingalpha · 07/30 16:13
Chi-Med Reports 2020 Interim Results and Provides Updates on Key Clinical Programs
– Strong global pipeline progress – three U.S. FDA1 Fast Track Designations; surufatinib U.S. NDA2 preparations underway; and initiation of global Phase III for fruquintinib – – Two further NDAs submitted in China – savolitinib in MET3 Exon 14 skipping mutati
GlobeNewswire · 07/30 12:47

所属板块

制药
+0.19%
制药与医学研究
+0.08%

热门股票

代码
价格
涨跌幅

HCM 简况

Hutchison China Meditech Limited is an investment holding company principally engaged in the manufacture and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Manufacturing Business segment is engaged in the manufacture and distribution of drug products. The Distribution Business segment provides sales and marketing services to pharmaceutical manufacturers. The Company's products include prescription and over the counter (OTC) pharmaceuticals such as banlangen, fu fang dan shen tablets and shexiang baoxin pills and others, and consumer health products. In addition, the Company also develops targeted therapeutics and immunotherapies for oncology and autoimmune diseases.
展开

微牛提供Hutchison China MediTech Limited(NASDAQ-HCM)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的HCM股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易HCM股票基本功能。